Vismodegib
- Generic Name
- Vismodegib
- Brand Names
- Erivedge
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14Cl2N2O3S
- CAS Number
- 879085-55-9
- Unique Ingredient Identifier
- 25X868M3DS
- Background
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling p...
- Indication
用于不能手术或放疗的局部晚期皮肤基底细胞癌患者和肿瘤已转移的患者。
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Metastatic Basal cell carcinoma
- Associated Therapies
- -
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Columbia University
- Registration Number
- NCT03767439
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- Conditions
- Interventions
- Drug: AlectinibDrug: VismodegibDrug: IpatasertibDrug: CarboplatinDrug: OlaparibDrug: ErlotinibDrug: CisplatinDrug: BevacizumabDrug: GemcitabineDrug: VemurafenibDrug: CobimetinibDrug: Trastuzumab Subcutaneous (SC)Drug: PertuzumabDrug: AtezolizumabDrug: PaclitaxelDrug: EntrectinibDrug: IvosidenibDrug: Pemigatinib
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 528
- Registration Number
- NCT03498521
- Locations
- 🇦🇺
Northern Cancer Institute, St Leonards, New South Wales, Australia
🇦🇺Blacktown Hospital, Blacktown, New South Wales, Australia
🇫🇮Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
- Conditions
- Interventions
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 720
- Registration Number
- NCT03297606
- Locations
- 🇨🇦
Verspeeten Family Cancer Centre, London, Ontario, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦BCCA - Kelowna, Kelowna, British Columbia, Canada
NCT Neuro Master Match - N²M² (NOA-20)
- Conditions
- Interventions
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University Hospital Heidelberg
- Target Recruit Count
- 228
- Registration Number
- NCT03158389
- Locations
- 🇩🇪
University Hospital Mainz, Neurosurgery, Mainz, Germany
🇩🇪University Hospital Heidelberg, Neurology Clinic, Heidelberg, Germany
🇩🇪University Hospital Frankfurt, Neurooncology, Frankfurt am Main, Germany
Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- SRH Wald-Klinikum Gera GmbH
- Target Recruit Count
- 40
- Registration Number
- NCT03035188
- Locations
- 🇩🇪
HELIOS Klinikum Erfurt, Erfurt, Germany
🇩🇪Klinikum Augsburg Süd, Augsburg, Germany
🇩🇪Charité - Universitätsmedizin Berlin, Berlin, Germany
To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Istituto Clinico Humanitas
- Target Recruit Count
- 14
- Registration Number
- NCT02956889
- Locations
- 🇮🇹
Istituto Clinico humanitas, Rozzano, Mi, Italy
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2017-10-24
- Target Recruit Count
- 40
- Registration Number
- NCT02694224
- Locations
- 🇪🇸
Clínica Universidad de Navarra, Pamplona, Navarra, Spain
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Anne Chang
- Target Recruit Count
- 16
- Registration Number
- NCT02690948
- Locations
- 🇺🇸
Stanford University School of Medicine, Palo Alto, California, United States
Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 67
- Registration Number
- NCT02674009
- Locations
- 🇩🇪
Klinik Johann Wolfgang von Goethe Uni; Klinik für Dermatologie, Venerologie und Allergologie, Frankfurt, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.